In response to COVID-19, Mzbio, Inc. and its labs are working on faster and more accurate PCR methods to diagnose the virus. By sharing ideas and collaborating with Harvard University and local hospitals, we hope to make greater progress together.


A simple work-flow platform for DNA absolute quantification that supports clinical diagnostics, drug development, and life science research. We work on fundamental technology innovations that make precision medicine accessible to everyone.


Core Product Line

Mzbio digital PCR M-1000 series
Fully automated and integrated
Desktop or portable device
High sensitivity
Rapid analysis

Mzbio digital PCR analysis kit (MobiChips and reagents)


Impact

20+

Disease Areas

10+

Collaborations

$1.5M+

Research Funding


Selected Partners

Harvard University

Massachusetts General Hospital

MIT

Brigham and Women’s Hospital